Jerome Birkenstock
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jerome Birkenstock has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Frauke Zipp
Department of Neurology, Focus Program Translational Neuroscience (FTN) and Immunotherapy (FZI), Rhine-Main Neuroscience Network (rmn2), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany
2 shared publications - Albrecht Stroh
Leibniz Institute for Resilience Research, Mainz, Germany
1 shared publication - Andrea Schnatz
Institute for Microanatomy and Neurobiology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, 55131, Germany
1 shared publication - Beatrice Wasser
Department of Neurology, Research Center for Immunotherapy (FZI) and Focus Program Translational Neuroscience (FTN), Rhine-Main Neuroscience Network (rmn2), University Medical Center of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany
1 shared publication - Catherine Larochelle
Department of Neurosciences, Faculty of Medicine, Université de Montréal, Montreal, Canada
1 shared publication - Cedric S. Raine
Robyn Klein (St. Louis, MO, USA
1 shared publication
Latest Publications
- Open Access
- 20 August 2021
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 118 (34)
Pro-inflammatory T helper 17 directly harms oligodendrocytes in neuroinflammation
Significance: Multiple sclerosis (MS) is a neuroinflammatory, demyelinating disease that represents one of the most frequent causes of irreversible disability in young adults. Treatment options to halt disability are limited. We discovered that T helper (Th)17 cells in contact with oligodendrocytes produce higher levels of glutamate and induce significantly greater oligodendrocyte damage than their Th2 counterpart. Blockade of CD29, which is linked to glutamate release pathways and expressed in high levels on Th17 cells, preserved human oligodendrocyte processes from Th17-mediated injury. Our data thus provide evidence for the direct and deleterious attack of Th17 cells on the myelin compartment and show the potential for therapeutic opportunities to protect oligodendrocytes’ myelinating processes in MS.
- 20 August 2021
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 118 (34)
Open AccessPro-inflammatory T helper 17 directly harms oligodendrocytes in neuroinflammation
Significance: Multiple sclerosis (MS) is a neuroinflammatory, demyelinating disease that represents one of the most frequent causes of irreversible disability in young adults. Treatment options to halt disability are limited. We discovered that T helper (Th)17 cells in contact with oligodendrocytes produce higher levels of glutamate and induce significantly greater oligodendrocyte damage than their Th2 counterpart. Blockade of CD29, which is linked to glutamate release pathways and expressed in high levels on Th17 cells, preserved human oligodendrocyte processes from Th17-mediated injury. Our data thus provide evidence for the direct and deleterious attack of Th17 cells on the myelin compartment and show the potential for therapeutic opportunities to protect oligodendrocytes’ myelinating processes in MS.
- 28 February 2018
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 10 (430)
Fast direct neuronal signaling via the IL-4 receptor as therapeutic target in neuroinflammation
Targeting neuronal interleukin-4 signaling is beneficial for clinical progression and axon pathology in different neuroinflammation models.
- 28 February 2018
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 10 (430)
Fast direct neuronal signaling via the IL-4 receptor as therapeutic target in neuroinflammation
Targeting neuronal interleukin-4 signaling is beneficial for clinical progression and axon pathology in different neuroinflammation models.